Blog Posts - Harvoni (sof/ldv)



Shorter HCV Tx Works in Advanced Disease

Provided by MedPage Today Twelve weeks of treatment yielded high efficacy rates in hepatitis C (HCV) patients with advanced liver disease or recurrent HCV after transplant. by Michael Smith North American Correspondent, MedPage Today VIENNA --...
by Hepatitis C Research and News on Apr 23, 2015

Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease

-- High Cure Rates in More Than 600 Genotype 1 and 4 Patients With Limited or No Approved Treatment Options -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 23, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 clinic...
by Hepatitis C Research and News on Apr 23, 2015

B.C covers two curative hepatitis C drugs

Monday, March 23, 2015 3:00 PM VICTORIA - British Columbia is providing public drug plan coverage of two new, often curative, hepatitis C drugs effective March 24, 2015, announced Minister of Health Terry Lake today. People with hepatitis C will be...
by Hepatitis C Research and News on Mar 25, 2015

FDA Safety Alert on Sovaldi/Harvoni Label Change

You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant lab...
by Hepatitis C Research and News on Mar 21, 2015

Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment

Published: Nov 11, 2014 8:02 a.m. ET - High Cure Rates in Nearly 800 HCV Patients with Advanced Liver Disease - BOSTON, Nov 11, 2014 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD, +0.55% today announced results from several Phase 2 and Phase 3 stu...
by Hepatitis C Research and News on Nov 11, 2014

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014 US surveyed specialists anticipate prescribing Gilead Sciences’ (Nasdaq: GILD) Harvoni to a high proportion of their genotype-1 infected hepatitis C virus (HCV) patients, including those with cirrhosis of the liver, even if it is listed...
by Hepatitis C Research and News on Nov 10, 2014


Trending Topics

Close